New Delhi: The Council of Scientific and Industrial Research (CSIR) and Hyderabad’s Laxai Life Sciences Private Limited have been given the regulatory approval by the Drugs Controller General of India (DCGI) to undertake a two-arm part-II scientific trial to evaluate the security and efficacy of the colchicine drug in enchancment of scientific outcomes throughout the therapy of Covid-19 sufferers.
The associate CSIR institutes on this vital scientific trial are the CSIR-Indian Institute of Chemical Technology (IICT), Hyderabad, and CSIR-Indian Institute of Integrative Medicine (IIIM), Jammu.
ALSO READ | No Tax On Black Fungus Drugs, Rates Slashed For Covid Essentials; 5% GST On Vaccines
CSIR Director General Dr Shekhar C. Mande expressed his delight on the approval granted to conduct the scientific trial on this authorised drug, which is used for treating gout and associated inflammatory situations.
CSIR Director General’s Advisor Dr Ram Vishwakarma highlighted that colchicine together with normal of care will likely be an vital therapeutic intervention for the Covid sufferers with cardiac co-morbidities and in addition for lowering professional-inflammatory cytokines, resulting in sooner restoration.
The DCGI nod comes as various international research have confirmed now that cardiac problems throughout course of the Covid-19 infections and post-Covid syndrome are resulting in lack of many lives and it’s important to search for new or repurposed medication.
Dr S. Chandrasekhar (Director CSIR-IICT, Hyderabad) and Dr D.S. Reddy (Director, CSIR-IIIM, Jammu) – the 2 associate institutes from CSIR – mentioned they’re wanting ahead to the result of this part-II scientific efficacy trial on colchicine, which can result in life-saving intervention within the administration of hospitalised sufferers.
“India is one of the largest producers of this key drug and if successful, it will be made available to the patients at an affordable cost,” mentioned a launch issued by the Ministry of Science and Technology.
ALSO READ |Â No Immediate Changes In Covishield Dose Gap, Scientific Evidence Collected To Review Decision In Next Meet
Laxai CEO Dr Ram Upadhayay on his half knowledgeable that the enrollment of sufferers has already begun at a number of websites throughout India and the trial is prone to be accomplished within the subsequent eight to 10 weeks.
“This drug can be made available to large population of India based on the results of this trial and regulatory approval,” he added.
The Ministry of Science and Technology mentioned current scientific research have reported in main medical journals about colchicine being related to a big discount within the charges of recurrent pericarditis, put up-pericardiotomy syndrome, and peri-procedural atrial fibrillation following cardiac surgical procedure and atrial fibrillation ablation.
Check out under Health Tools-
Calculate Your Body Mass Index ( BMI )
